Recordati SpA (Recordati SpA) Debt-to-EBITDA : 2.79 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Recordati SpA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $497 Mil. Recordati SpA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,476 Mil. Recordati SpA's annualized EBITDA for the quarter that ended in Dec. 2023 was $706 Mil. Recordati SpA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.79.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Recordati SpA's Debt-to-EBITDA or its related term are showing as below:

RCDTF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.95 Med: 1.65 Max: 3.07
Current: 2.55

During the past 13 years, the highest Debt-to-EBITDA Ratio of Recordati SpA was 3.07. The lowest was 0.95. And the median was 1.65.

RCDTF's Debt-to-EBITDA is ranked worse than
60.91% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs RCDTF: 2.55

Recordati SpA Debt-to-EBITDA Historical Data

The historical data trend for Recordati SpA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Debt-to-EBITDA Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

2.05

1.87

1.72

3.07

2.55

Recordati SpA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															3.09	1.90	2.60	2.87	2.79

Competitive Comparison of Recordati SpA's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Recordati SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Debt-to-EBITDA falls into.

Recordati SpA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Recordati SpA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(496.929	+	1475.699)	/	772.559
	=	2.55

Recordati SpA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(496.929	+	1475.699)	/	706.388
	=	2.79

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Recordati SpA (OTCPK:RCDTF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Recordati SpA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (Recordati SpA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy� (ARS-1; epinephrine nasal spray)

By PRNewswire PRNewswire • 09-22-2020

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa� (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology

By Business Wire Business Wire • 08-31-2022

Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing's Disease

By Business Wire Business Wire • 06-17-2020

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing's Disease Published in Lancet Diabetes & Endocrinology

By Business Wire Business Wire • 07-28-2020

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)

By Business Wire Business Wire • 06-02-2020

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa� (Osilodrostat) in Patients With Cushing's Disease

By Business Wire Business Wire • 03-29-2022

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany

By Business Wire Business Wire • 07-16-2020

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire • 03-09-2020